Trial Profile
Phase I, open label, dose-escalation study followed by a safety expansion part to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor), administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL))
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs UCART 19 (Primary) ; Alemtuzumab; Cyclophosphamide; Fludarabine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Acronyms CALM
- Sponsors Servier
- 04 Mar 2021 According to a Cellectis media release, pooled results of CALM and PALL studies published in the Lancet journal.
- 15 Sep 2020 Status changed from recruiting to completed.
- 07 Sep 2020 This trial has been completed in France (Date of the global end of the trial: 30 July 2020).